Again, PRN blood pressure medications for asymptomatic hypertension in hospitalized patients causes harm:
pubmed.ncbi.nlm.nih.gov/39585709/
16.01.2025 13:35
👍 20
🔁 9
💬 2
📌 2
Again, PRN blood pressure medications for asymptomatic hypertension in hospitalized patients causes harm:
pubmed.ncbi.nlm.nih.gov/39585709/
It’s wild how everyone determines their initial diuretic dosing. Crazy to think we still don’t know what’s best with all the data that exists out there. We tried looked at “optimal” initial dosing as 2x the home dose here: www.jacc.org/doi/10.1016/...
New publication co-led with Griffin Bullock!
📊 Wide variability in IV diuretic dosing for acute HF, even within a single institution.
⏱️ Delays in 1st, 2nd, & max doses = longer hospital stays. #CardioSky #PharmSKy www.sciencedirect.com/science/arti...
You can now watch this #JACC Journal Club's #AHA24 webinar discussing #SUMMIT CMR Substudy on Youtube
www.youtube.com/watch?v=61rd...
#CardioSky #MedSky
@chriskramermd.bsky.social @natstokes.bsky.social @jaccjournals.bsky.social @accintouch.bsky.social
Can AI automate HF adjudication in global clinical trials?
Our latest #AHA2024 SimPub
@CircHF
In the DELIVER trial, our AI model for HF hosp was
-Accurate
-Generated identical treatment estimate for dapa as human CEC
-Extracts evidence of HF
Paper: twtr.to/7qxb_
My comments on the KRAKEN trial of #muvalaplin to Medscape. #lipids #LPa #CardioSky #AHA24
#AHA24 #CardioSky #MedSky
Dr. Cornelio discusses strategies for how to deprescribe
Some include CDS 💻 & patient decision aids/education 📚
Dr. Mehling offers insight into truly how toxic NSAIDs are
- 3x 🫀dz risk
- ⬆️ SBP by 14 mmHg
Dr. Orkaby up next with a geriatrician viewpoint!
- We prescribe complex and overwhelming “guideline-based regimen” for patients
- Careful about the prescribing cascade
- we do have a framework for de-prescribing in 🫀💊 to help cardiology clinicians
3️⃣ not clear outcomes or great evidence in de-prescribing so far - huge need for future methodology and research
Some potential high-value targets do exist though!
Now Dr. Hernandez talks about some potential issues with de-precribing. Will we make it worse??💊
1️⃣ trust in science 🧪🔬- it’s worsening over time and pretty low in the US
2️⃣ will sending mixed messages delay or prevent important med use like GDMT in HFrEF
What are potential targets in CVD?
- ASA with AC
- HF-exacerbating 💊 (NSAIDs, TZDs)
- Inappropriate DOAC dosing
- 💊 w/o indications (ex: nitrates for angina post PCI, or even BB in HFpEF?)
- 💊 w/ low likelihood of benefit (ex: palliative care)
Dr. Goyal talks about complications from polypharmacy 💊💊💊
- Adherence, ADRs, and lack of optimization, especially GDMT in HFrEF 🫀
- Need to focus on practical prescribing ⬆️ and de-prescribing ⬇️ rules
Lots of tools to help with de-prescribing. But where is the sweet “Goldilocks” spot? We don’t quite know yet
What do we need to focus on de-prescribing on CVD?
Dr. Schwartz gives a good state of the field. Polypharmacy 💊💊 + age = higher complications & 💊🚫 interactions. Huge need to systematically withdrawal low-value “inappropriate” medications #AHA24 #CardioSky
Graphic listing new Fellows of the American Heart Association
Graphic listing new Fellows of the American Heart Association
Congratulations to these new FAHAs! 👏 🎉 🙌 Help us welcome them to the family. #AHA24
#AHA24 #CardioSky #MedSky
AHA @americanheart.bsky.social
ACC @accintouch.bsky.social
AHA Sciences @ahascience.bsky.social
AHA Journals @ahajournals.bsky.social
JAMA @jamacurrent.bsky.social
ASPC @aspcardio.bsky.social
Am J Prev Card @ajpcardio.bsky.social
J Card Fail @jcardfail.bsky.social
Natural Language Processing to Adjudicate Heart Failure Hospitalizations in Global Clinical Trials
www.ahajournals.org/doi/10.1161/...
#Circulation #AHA24 #CardioSky #MesSky
@ahajournals.bsky.social @ahascience.bsky.social
CRISPR-Cas9 Gene Editing with Nexiguran Ziclumeran for ATTR Cardiomyopathy
www.nejm.org/doi/full/10....
#NEJM #AHA24 #CardioSky #MedSky
@ahascience.bsky.social @dramitkhera.bsky.social
#AHA24 #CardioSky
@ahascience.bsky.social
Lyndsey DeGroot from CU presenting findings from the ADAPT RCT! #AHA24
jamanetwork.com/journals/jam...
Amazing @erinmichos.bsky.social teaching us about new drugs & technologies in lipid management
Love seeing 🦋 on her slides.
#AHA24 #CardioSky #MedSky #WIC
@ahascience.bsky.social @aspcardio.bsky.social @dramitkhera.bsky.social @drmarthagulati.bsky.social @minnowwalsh.bsky.social
#AHA24 #CardioSky #MedSky #WIC #CardioObstetrics
Go Red For Women and Underrepresented Populations
Join us now in Main Event II
@garimasharmamd.bsky.social @ahascience.bsky.social
@minnowwalsh.bsky.social @drmarthagulati.bsky.social @dramitkhera.bsky.social
Happening now in Main II. All about Heart Disease in women. #AHA24 #cardiosky
Dr Minc on strategies to tackle geographical disparities in #PAD “amputation hot spots” in WV using implementation science, provider ed on foot exam and #PAD, “hot foot hotline” #AHA24 #Cardiosky
@TheLancet session at #AHA24 starting now! #obesity
🫀Malnutrition was a problem but now obesity is taking over worldwide with few exceptions
🫀Severe obesity has also ⤴️
🫀BMI doesn’t reflect obesity as well as waist-to-height ratio
🫀⤴️ diabetes follows obesity
Happening now in N226! Come explore the intersection between obesity and heart failure. What type of fat is it? 🤗🤔😀 #AHA24 #HEATAF #adipocyteheterogeneity #hotfat #standingroomonly @ahascience.bsky.social
#AHA24 version of #Skytorial for #CardioSky newcomers
1/2
🦋 Unlike Twitter, liking a post does NOT promote or increase visibility of that post.
You need to REPOST.
🦋 Follow #CardioSky community by using this starter pack
go.bsky.app/562nfhZ
#MedSky
@ahascience.bsky.social
2️⃣ LLMs can reduce burden for patient eligibility screening in clinical trials, using RECTIFIER. 78% ⬆️ in eligibility determination vs. manual.